medigraphic.com
ISSN 1996-3521 (Electronic)

2023, Number 40

<< Back Next >>

INFODIR 2023; 19 (40)

Efficiency of the use of prophylactic immunotherapy with palivizumab in premature infants

Jiménez HLG

Language: Spanish
References: 57
Page: 1-26
PDF size: 515.96 Kb.


ABSTRACT

Introduction: Palivizumab is a prophylactic monoclonal antibody against respiratory syncytial virus of high cost and unknown efficacy.
Objective: To evaluate the efficiency of immunotherapy with palivizumab in preterm infants in the Costa Rican social security system.
Methods: A full economic evaluation was conducted in the period 2010-2017, with a time horizon of one year, no discount rate from the perspective of social security and cost data in US dollars. Seven high-complexity hospitals were included and complemented by a budget impact analysis (2018-2021). Selected clinical records were reviewed after the attrition procedure of preterm infants receiving palivizumab (n = 200) and preterm infants receiving the traditional clinical alternative (n = 206). The simplest sensitivity analysis was performed which is univariate by considering the mean value plus minus two standard deviations.
Results: The majority of preterm infants belonged to low-income households and mothers with low educational level. Efficiency was favourable for innovative palivizumab therapy by generating health benefits according to gestational age group and hospital stay. The average cost of treatment was highly sensitive to a range of factors. Universalisation of immunotherapy generated increases in institutional budget commensurate with the scenario selected.
Conclusions: The use of palivizumab is an efficient alternative according to the gestational age of the preterm infant and hospital stay, with generalised use producing a budget increase that must be weighed given the benefits obtained.


REFERENCES

  1. Narayan O, Bentley A, Mowbray W, Hermansson M, Pivonka D, Ngonga E, et al. Updated cost-effectiveness analysis of palivizumab (Synagis) for the prophylaxis of respiratory syncytial virus in infant populations in the UK. Journal of Medical Economics. 2020 [acceso 03/07/2020];1-15. Disponible en: https://pubmed. ncbi. nlm. nih. gov/33107769/

  2. Camps J, Calzado D, Galano Z, Perdomo J. Infecciones respiratorias agudas pediátricas. Un acercamiento a bronquiolitis. Rev Inf Cient. 2015 [acceso 03/04/2020];90(2):391-400. Disponible en: http://www. revinfcientifica. sld. cu/index. php/ric/article/view/257/1104

  3. Evans R, Brenes D. Mortalidad en menores de cinco años en Costa Rica 1920-2009. Rev. Costarric. Salud Pública. 2017 [acceso 04/05/2020];26(1):11-21. Disponible en: http://www. scielo. sa. cr/pdf/rcsp/v26n1/1409-1429-rcsp-26-01-00011. pdf

  4. Sarna M, Lambert S, Sloots T, Whiley D, Alsaleh A, Mhango L, et al. Viruses causing lower respiratory symptoms in young children: findings from the ORChID birth cohort. Thorax. 2018 [acceso 06/06/2020];73:969-79. Disponible en: https://thorax. bmj. com/content/thoraxjnl/73/10/969. full. pdf

  5. Gimferrer L, Campins A, Codina M, Rodrigo J, Melendo S, Martín M, et al. Circulation of a novel human respiratory syncytial virus Group B genotype during the 2014-2015 season in Catalonia (Spain). Clin Microbiol Infect. 2016 [04/05/2020];22(1):97-8. Disponible en: https://pubmed. ncbi. nlm. nih. gov/26408279/

  6. Goldstein E. Pediatric hospitalizations associated with respiratory syncytial virus (RSV) and influenza, and the frequency of asthma as a secondary diagnosis. London: BioRxiv. 2017 [acceso 04/03/2020]. Disponible en: https://www. biorxiv. org/content/biorxiv/early/2017/07/10/161067. full. pdf

  7. Lee S, Kwok K, Ng D, Hon K. Palivizumab for Infants < 29 Weeks in Hong Kong without a Clear-Cut Season for Respiratory Syncytial Virus Infection-A Cost-Effectiveness Analysis. J Trop Pediatrics. 2017 [acceso 04/03/2018];64(5):418-25. Disponible en: https://academic. oup. com/tropej/advance-article-abstract/doi/10. 1093/tropej/fmx086/4587611?redirectedFrom=fulltext

  8. López K, Ramírez A. La constitucionalización de la economía social de mercado en Colombia. Advocatus. 2017 [acceso 02/02/2020];14(28):151-74. Disponible en: https://revistas. unilibre. edu. co/index. php/advocatus/article/view/895

  9. Calderón G. Prevalencia y complicaciones pulmonares asociadas a ventilación mecánica en recién nacidos ingresados en el área de neonatología del Hospital Municipal de la Mujer y el Niño [Tesis de Licenciatura en Medicina en Internet]. Ecuador: Universidad Católica de Cuenca. 2017 [acceso 03/02/2020];1-62. Disponible en: http://dspace. ucacue. edu. ec/bitstream/reducacue/7522/1/9BT2017-MTI55. pdf

  10. Instituto Nacional de Estadísticas y Censos INEC. Estadísticas de Costa Rica. Costa Rica: INEC; 2017 [acceso 03/02/2020]. Disponible en: http://www. inec. go. cr/

  11. Costa Rica: estadísticas regionales 2010-2015, MIDEPLAN. Costa Rica: Ministerio de Planificación y Política Económica de Costa Rica; 2017 [acceso 03/04/2020] p. 1-108. Disponible en: https://n9. cl/qoaqa

  12. Rodríguez O, Morales S, Norheim O, Wilson B. Revisiting Health Rights Litigation and Access to Medications in Costa Rica: Preliminary Evidence from the Cochrane Collaboration Reform. Health and Human Rights Journal. 2018 [acceso 03/01/2020];20(1):79. Disponible en: https://n9. cl/5sgh0

  13. Caja Costarricense de Seguro Social CCSS. Costa Rica. Lista Oficial de Medicamentos (LOM). Costa Rica: CCSS. 2016 [acceso 08/01/2020];1-321. Disponible en: www. binasss. sa. cr/lom2016. pdf

  14. Graham B. Vaccine development for respiratory syncytial virus. Current opinionin Virology. 2017 [acceso 18/01/2020];23:107-12. Disponible en: https://www. ncbi. nlm. nih. gov/pubmed/28525878

  15. Olicker A, Li H, Tatsuoka C, Ross K, Trembath A, Hibbs M, et al. Have changingpalivizumab administration policies led to more respiratory morbidity in infants born at 32-35 weeks? J Pediatr. 2016 [acceso 03/01/2020];171:31-7. Disponible en: https://doi. org/10. 1016/j. jpeds. 2015. 11. 040

  16. Jiménez L. Análisis crítico de artículos científicos sobre tecnologías en saludcontra el virus sincitial respiratorio. Rev Cubana Farm. 2019 [acceso 18/02/2020];52(29):e314. Disponible en: http://www. revfarmacia. sld. cu/index. php/far/article/view/314/234

  17. Caja Costarricense de Seguro Social CCSS. Departamento de Estadísticas delHospital Nacional de Niños “Dr. Carlos Saenz Herrera”. Costa Rica: HNN; 2010-2017;2017 [acceso 21/02/2020]. Disponible en: https://www. ccss. sa. cr/hospitales?v=21

  18. Jiménez L, Gálvez A. Componentes económicos del contexto costarricense quese relacionan con la salud universal. 2019 [acceso 23/01/2020];28(julio-diciembre):123-37 Disponible en: http://revinfodir. sld. cu/index. php/infodir/article/view/588

  19. Jiménez L, Collazo M, González A. Costo-efectividad incremental delpalivizumab en prematuros en la Seguridad Social de Costa Rica. 2010-2017. Revista Horizonte sanitario. 2020;19(2):195-207. DOI: https://doi. org/10. 19136/hs. a19n2. 3623

  20. Jiménez L, Collazo M, González A. Valoración económica del palivizumab enprematuros en la Seguridad Social en Costa Rica 2013-2017. Revista Cubana de Farmacia. 2020 [acceso 18/06/2020];53(2):e367. Disponible en: http://www. revfarmacia. sld. cu/index. php/far/article/view/367

  21. Jiménez L, Collazo M, González A. Análisis de impacto presupuestario delpalivizumab en la seguridad social de Costa Rica. Revista Naturalia Patagónica. 2020 [acceso 05/05/2020];16:6-16. Disponible en: http://www. fcn. unp. edu. ar/sitio/naturalia/

  22. Giersing B, Karron R, Vekemans J, Kaslow D, Moorthy V. Meeting report: WHO consultation on respiratory syncytial virus (RSV) vaccine development. Vaccine. 2017 [acceso 03/04/2020];S0264-410X(17)30293-1. Disponible en: https://www. sciencedirect. com/science/article/pii/S0264410X17302931

  23. Jiménez L. Resultados del uso de palivizumab en la seguridad social de Costa Rica. Revista Vitae Facultad de Ciencias Farmacéuticas y Alimentarias, Medellín, Colombia. 2019 [acceso 10/03/2020];26(1):S137-44. Disponible en: www. revistas. udea. edu. co

  24. Homaira N, Rawlinson W, Snelling T, Jaffe A. Effectiveness of palivizumab in preventing RSV hospitalization in high risk children: A real world perspective. International Journal of Pediatrics. 2014 [acceso 18/03/2020];1-14. Disponible en: https://www. ncbi. nlm. nih. gov/pubmed/25548575

  25. McLaurin K, Wade S, Diakun D, Stewart D. Respiratory Syncytial virus hospitalization outcomes and costs of full term and preterm infants. J Perinatol. 2016 [acceso 05/04/2020];36:990-96. Disponible en: https://www. ncbi. nlm. nih. gov/pubmed/27490190

  26. Choueiry E, Gerbaka B, Hanna N, Fenianos A. Cost effectiveness of palivizumab in prevention against RSV hospitalizations in risk groups. J Pediatr Care. 2016 [acceso 04/02/2020];2(3):19. Disponible en: http://pediatrics. imedpub. com/costeffectiveness-of-palivizumab-in-prevention-against-rsv-hospitalizations-in-risk-groups. php?aid=17550

  27. Ginsberg G, Somekh E, Schlesinger Y. Should we use palivizumab immunoprophylaxis for infants against respiratory syncytial virus? a cost utility analysis. Journal of Health Policy Research. 2018 [acceso 04/02/2020];7(63):1-14. Disponible en: https://ijhpr. biomedcentral. com/track/pdf/10. 1186/s13584-018-0258-4

  28. Olchansky N, Hansen R, Pope E, D´Cruz B, Fergie J, Goldstein M, et al. Palivizumab prophylaxis for Respiratory Syncytial Virus: Examining the evidence around value. Open Forum Infections Diseases. 2018 [acceso 04/03/2020];5(3):ofy031. Disponible en: https://www. ncbi. nlm. nih. gov/pmc/articles/PMC5833316/

  29. Salinas G, Martínez S, Reyes A, Garduño J, Muñoz, O, Granados, V, et al. Cost effectiveness analysis of the use of pavilizumab in the prophylaxis of preterm patients in México. Salud Pública Méx. 2012 [acceso 01/02/2020];54(1):47-59. Disponible en: https://www. repository. fedesarrollo. org. co/handle/11445/267

  30. Shing R, Ka K, Keung D, Hon K. Palivizumab for infants < 29 weeks in Hong Kong without a clear cut season for respiratory syncytial virus infection: A cost effectiveness analysis. J Trop Pediatrics. 2017 [acceso 02/03/2020];1-8. Disponible en: https://www. ncbi. nlm. nih. gov/pubmed/29106671

  31. Neovius K, Buesch K, Sandström K, Neovius M. Cost effectiveness analysis of palivizumab as respiratory syncytial virus prophylasis in preterm infants in Sweden. Acta Paediatrica. 2011 [acceso 18/01/2020];100:1306-14. Disponible en: https://www. ncbi. nlm. nih. gov/pubmed/21477089

  32. Bentley A, Filipovic I, Gooch K, Busch K. A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in Infants in the United Kingdom. Health econ rev. 2013 [acceso 18/0172020];3(1):18. Disponible en: https://www. ncbi. nlm. nih. gov/pubmed/23919494

  33. Paes B, Carbonell X. Respiratory syncytial virus prophylaxis for children with chronic lung disease: ¿have we got the criteria right? Expert Review of Anti infective Therapy. 2019;17(4):211-22. DOI: https://doi. org/10. 1080/14787210. 2019. 1581062

  34. Fernández S, Albas D, Satragno D, Cattaino A, Martin M, Rubio C, et al. Recomendaciones sobre el uso de palivizumab. Actualización 2015. Arch Argent Pediatr. 2016 [acceso 03/0272020];114(1):84-8. Disponible en: https://www. sap. org. ar/uploads/consensos/recomendaciones-sobre-el-uso-de-palivizumab-nbspactualizaci-oacuten-2015. pdf

  35. Gonzales V, Lake J, Martínez E, LaFleur J. Synagis for respiratory syncytial virus prophylasis. UTAH, USA: Medicaid Dur Report; 2018 [acceso 03/04/2020]. p. 1-31. Disponible en: https://medicaid. utah. gov/pharmacy/drugutilization/files/Criteria%20Review%20Documents/2018/2018. 04%20Synagis. pdf

  36. Nuijten M, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ. 2010 [acceso 23/02/21];11:105-15. Disponible en: https://link. springer. com/article/10. 1007%2Fs10198-009-0206-x

  37. United Health Care Oxford UHCO. Synagis (Palivizumab) Oxford: Pharmacy UHC; 2018 [acceso 18/08/2020]. p. 1-9. Disponible en: https://www. uhcprovider. com/content/dam/provider/docs/public/policies/medicaid-comm-plan/synagis-palivizumab-cs. pdf

  38. Pim K, Huey S. Systematic review of the safety and efficacy of palivizumab among infants and young children with cystic fibrosis. Pharmachotherapy. 2017 [acceso 03/02/2020];378(6):755-69. Disponible en: https://www. ncbi. nlm. nih. gov/pubmed/28423192

  39. Claydon J, Sur A, Callejas A, Ladd M, Kwan E, Taylor R, et al. Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen. PloS One. 2017 [acceso 18/11/2019];12(4):e0176152. Disponible en: https://journals. plos. org/plosone/article?id=10. 1371/journal. pone. 0176152

  40. Zhao M, Zheng Z, Chen M, Modjarrad K, Zhang W, Zhan L, et al. Discovery of a prefusion RSV F-specific monoclonal antibody that provides greater in vivo protection than the murine precursor of Palivizumab. J Virol. 2017 [acceso 03/02/2020];176(17):44. Disponible en: https://jvi. asm. org/content/jvi/early/2017/05/18/JVI. 00176-17. full. pdf

  41. Kinnear E, Lambert L, McDonald J, Cheeseman H, Caproni L, Tregonin J, et al. Airway T cells protect against RSV infection in the absence of antibody. Mucosal Immunol. 2018 [acceso 03/02/2020];11(1):249-55. Disponible en: https://spiral. imperial. ac. uk/bitstream/10044/1/49273/6/Accpeted%20final. pdf

  42. Shahabi A, Peneva D, Incerti D, McLaurin K, Stevens W. Assesing variation in the cost of palivizumab for Respiratory Syncytial Virus prevention in preterm infants. Pharmacoeconomics Open. 2018 [acceso 03/02/2020];2:53-61. Disponible en: https://link. springer. com/article/10. 1007/s41669-017-0042-3-146

  43. Glick A, Kjelleren S, Hofstetter A, Subramony A. RSV hospitalizations in comparison with regional RSV activity and inpatient palivizumab administration, 2010-2013. Hosp pediatr. 2017 [acceso 28/11/2019];7(5):271-80. Disponible en: https://hosppeds. aappublications. org/content/hosppeds/early/2017/04/04/hpeds. 2016-0124. full. pdf

  44. Sánchez A, Burgos R, Oyagüez I, Aloy F, Sánchez M, Martinón F, et al. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. BMC Infect Dis. 2017 [acceso 01/01/2020];17(687):1-11. Disponible en: https://www. ncbi. nlm. nih. gov/pubmed/29041909

  45. Figueras J, Carbonell X, Quero J, Fernandez B, Guzman J, Echaniz I, et al. Efectividad de palivizumab en la prevención de la infección por el virus respiratorio sincitial en prematuros de 321 a 350 semanas de gestación en España. Acta Pediatr Esp. 2010 [acceso 23/02/21];68(1):13-18. Disponible en: https://www. proquest. com/openview/ecfacd9e177d03b086ea55cc3e2059c7/1?pq-origsite=gscholar&cbl=31418

  46. Guier A. Hospitalización prevenible con el uso de palivizumab en pacientes prétermino, oxigenodependientes por enfermedad pulmonar crónica neonatal; estudio retrospectivo de casos y controles en el Hospital Nacional de Niños Dr. Carlos Sáenz Herrera en el período enero 2007 y enero 2011 [Tesis de Maestría]. Costa Rica: Universidad de Costa Rica. 2014 [acceso 18/11/2019];1-38. Disponible en: http://repositorio. sibdi. ucr. ac. cr:8080/jspui/handle/123456789/4075

  47. Lim A, Butt M, Dix J, Elliott L, Paes B. Respiratory syncytial virus (RSV) infection in children with medical complexity. Eur J Clin Microbiol Infect Dis. 2019 [acceso 18/01/2020];38(1):171-6. Disponible en: https://link. springer. com/content/pdf/10. 1007%2Fs10096-018-3409-1. pdf

  48. López M. Complicaciones de la ventilación mecánica en los neonatos de la unidad de cuidados intensivos neonatales [Tesis de Licenciatura en Medicina]. Ecuador: Universidad de Guayaquil - Facultad de Ciencias Médicas. Carrera de Medicina; 2018 [acceso 03/01/2020]. p. 1-50. Disponible en: http://repositorio. ug. edu. ec/bitstream/redug/30998/1/CD-2422-TESIS-LOPEZ%20GALAN. pdf

  49. Mauskopt J, Margulis A, Samuel M, Lohr K. Respiratory syncytial virus hospitalization in healthy preterm infants: systematic review. Pediatr Infect Dis. 2016 [acceso 23/02/21];35:e229-38. Disponible en: https://www. ncbi. nlm. nih. gov/pubmed/27093166

  50. Hernández Y, Lombardero M, Ortega C, Maciuniak P, Díez A. Cost effectiveness of a protocol using palivizumab in preterm infants. Farm Hosp. 2017 [acceso 28/01/2020];41(2):169-86. Disponible en: http://scielo. isciii. es/pdf/fh/v41n2/2171-8695-fh-41-02-00169. pdf

  51. Lázaro P, Figueras J, Doménech E, Echániz I, Closa R, Wood M, et al. La eficiencia (coste-efectividad) de palivizumab como profilaxis para la infección por virus respiratorio sincitial en prematuros de 32-35 semanas en España. An Pediatr. 2006 [acceso 03/01/2020];65(4):316-24. Disponible en: https://www. sciencedirect. com/science/article/pii/S169540330670203X

  52. Setzuko T, Isoyama S, Nieri P, Keiko H. Uso profilático de palivizumabe na prevenção de infecção pelo vírus sincicial respiratório em crianças de alto risco. BIS. Boletim do Instituto de Saúde. 2006 [acceso 28/01/2020];14(2):213-20. Disponible en: http://periodicos. ses. sp. bvs. br/pdf/bis/v14n2/v14n2a12. pdf

  53. Sharif S, Sharif H, Sharif N, Su Y, Sharif R. RSV infection in Nunavut cost analysisand associated risk factors: implication of vaccination program and public health planning. Vaccines and Immunol Open Access J. 2018 [acceso 24/01/2020];1(1):26-36. Disponible en: http://ologyjournals. com/vioaj/vioaj_00007. pdf

  54. Sanabria S. Caracterización de los pacientes con infecciones del tractorespiratorio inferior que ameritaron cuidado intensivo en el Hospital Nacional de Niños Dr. Carlos Sáenz Herrera durante los primeros 45 días del brote de infecciones del año 2014 [Tesis de maestría]. Costa Rica: Universidad de Costa Rica; 2015 [acceso 11/11/2019]. p. 1-29. Disponible en: http://repositorio. sibidi. ucr. ac. cr. 8080/jspui//handle/123456789/4053

  55. Ramos J, Moreno D, Gutiérrez M, Hernández A, Cordón A, Milano G, et al. Predicción de la evolución de la bronquiolitis por virus respiratorio sincitial en lactantes menores de 6 meses. Rev Esp Salud Pública. 2017 [acceso 18/01/2020];91:e1-e18. Disponible en: https://www. scielosp. org/pdf/resp/2017. v91/201701006/es

  56. Capizzi A, Silvestri M, Orsi A, Cutrera R, Rossi G, Sacco O, et al. The impact of therecent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence. Italian journal of pediatrics. 2017 [acceso 24/01/2020];43(1):71-5. Disponible en: https://ijponline. biomedcentral. com/track/pdf/10. 1186/s13052-017-0390-8

  57. Carbalho N, Jit M, Cox S, Yoong J, Hutubessy R. Capturing budget impactconsiderations within economic evaluations: A systematic review of economic evaluations of rotavirus vaccine in low- and middle-income countries and a proposed assessment framework. PharmacoEconomics. 2018 [acceso 15/02/2020];36:79-90. Disponible en: https://link. springer. com/content/pdf/10. 1007%2Fs40273-017-0569-2.pdf




2020     |     www.medigraphic.com